The subject matter of the invention is a pharmaceutical active ingredient consisting exclusively of the combination of (lS,3R,4R,5R)-3-{[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoyl]oxy}-1,4,5-trihydroxycyclohexanecarboxylic acid and methyl (2S,3E,4S)-4-{2-[2-(3,4- dihydroxyphenyl)ethoxy]-2-oxoethyl}-3-ethylidene-2-(P-D-glucopyranosyloxy)-3,4-dihydro-2H-pyran-5-carboxylate for use as a medicine or veterinary product, in particular in the prevention and/or treatment of pathological carbohydrate and/or lipid metabolism disorders.
